We strongly advise you to harness analysis of Infinity Pharmaceuticals fundamentals to see if markets are presently mispricing the organization. We found thirty-five available reported financial drivers for Infinity Pharmaceuticals which can be compared to its competitors. To make sure the equity is not overpriced, please check out all Infinity Pharmaceuticals fundamentals including its Shares Owned by Institutions, Net Income, Short Ratio, as well as the relationship between Price to Sales and Debt to Equity . Please also validate Infinity Pharmaceuticals Price to Earning to confirm the company can sustain itself down the road.Use Infinity Pharmaceuticals to protect against small markets fluctuations. The stock experiences very speculative upward sentiment.. Check odds of Infinity Pharmaceuticals to be traded at $1.615 in 30 days
Infinity Pharmaceuticals Valuation Over Time
Infinity Pharmaceuticals Company SummaryInfinity Pharmaceuticals competes with NantKwest, Del Mar, VBI Vaccines, and Vascular Biogenics. Its lead product candidate includes IPI145 an oral inhibitor of the delta and gamma isoforms of phosphoinositide3kinase for the treatment of hematologic malignancies. Infinity Pharmaceuticals Inc is developing DYNAMO which is in Phase II study to evaluate the safety and efficacy of IPI145 dosed at 25 mg CONTEMPO that is in the Phase IbII study of IPI145 in combination with obinutuzumab or rituximab in patients with untreated follicular lymphoma BRAVURA which is in Phase III study to evaluate the safety and efficacy of IPI145 plus rituximab and bendamustine and FRESCO that is in Phase II study to evaluate the safety and efficacy of IPI145 plus rituximab. It is also developing DYNAMOR which is in Phase III randomized study to evaluate IPI145 dosed at 25 mg in combination with rituximab a monoclonal antibody treatment DUO that is in randomized Phase III monotherapy study evaluating IPI145 dosed at 25 mg in patients with relapsed or refractory chronic lymphocytic leukemia and SYNCHRONY which is in the Phase Ib study of IPI145 in combination with obinutuzumab in CLL patients. In addition Infinity Pharmaceuticals Inc is conducting a Phase IbII trial of IPI145 in combination with venetoclax a Bcell lymphoma 2 inhibitor and developing IPI549 that is in Phase I study for patients with various solid tumors including melanoma and nonsmall cell lung cancer. Infinity Pharmaceuticals Inc has collaboration and license agreement with AbbVie Inc. to develop and commercialize IPI145 in oncology and development and license agreement with Intellikine Inc. to discover develop and commercialize pharmaceutical solutions targeting the delta andor gamma isoforms of PI3K. Infinity Pharmaceuticals Inc. is headquartered in Cambridge Massachusetts.
Infinity Pharmaceuticals Short Ratio vs Cash Flow from Operations
Infinity Pharmaceuticals Inc is rated second overall in short ratio category among related companies. It is rated fourth overall in cash flow from operations category among related companies .